These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23161334)

  • 21. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
    Iqbal S; Lenz HJ; Gandara DR; Shibata SI; Groshen S; Synold TW; Newman EM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):85-91. PubMed ID: 23712328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
    Attard G; Kitzen J; Blagden SP; Fong PC; Pronk LC; Zhi J; Zugmaier G; Verweij J; de Bono JS; de Jonge M
    Br J Cancer; 2007 Nov; 97(10):1338-43. PubMed ID: 18000498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
    Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
    Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
    Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
    Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
    Masters GA; Brockstein BE; Mani S; Ratain MJ
    Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
    Halmos B; Jia Y; Bokar JA; Fu P; Adelstein DJ; Juergens R; Rodal MB; Dowlati A
    Invest New Drugs; 2013 Oct; 31(5):1244-50. PubMed ID: 23553066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
    Chow LQ; Gustafson DL; O'Bryant CL; Gore L; Basche M; Holden SN; Morrow MC; Grolnic S; Creese BR; Roberts KL; Davis K; Addison R; Eckhardt SG
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):65-74. PubMed ID: 18320191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
    J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
    Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
    Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
    Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
    Ernst T; Merx K; Gnad-Vogt U; Lukan N; Kripp M; Schultheis B; Hochhaus A; Hofheinz RD
    Br J Cancer; 2007 Dec; 97(11):1475-9. PubMed ID: 18000507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
    Blagden SP; Molife LR; Seebaran A; Payne M; Reid AH; Protheroe AS; Vasist LS; Williams DD; Bowen C; Kathman SJ; Hodge JP; Dar MM; de Bono JS; Middleton MR
    Br J Cancer; 2008 Mar; 98(5):894-9. PubMed ID: 18319713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
    Margalit DN; Haddad RI; Tishler RB; Chau NG; Schoenfeld JD; Bakst RL; Misiukiewicz KJ; Gupta V; Posner M; Hanna GJ; Mahmood U; Rawal B; Catalano PJ; Rath L; Bacay A; McHugh P; Rabinowits G
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):132-139. PubMed ID: 31082494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
    Bahleda R; Varga A; Bergé Y; Soria JC; Schnell D; Tschoepe I; Uttenreuther-Fischer M; Delord JP
    Br J Cancer; 2018 Feb; 118(3):344-352. PubMed ID: 29337963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.